These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37952844)

  • 41. Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany.
    Conti A; Leorin M; Bogazzi IC; Renzi N; Pepe G; Frosini F; Furesi L; Dalla Tomasina L; Pennati P; Ghiadoni L;
    Crit Pathw Cardiol; 2024 Jun; 23(2):58-72. PubMed ID: 38781079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
    Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
    J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study.
    Wilsey HA; Bailey AM; Schadler A; Davis GA; Nestor M; Pandya K
    J Intensive Care Med; 2021 May; 36(5):597-603. PubMed ID: 32242482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis.
    Orso D; Fonda F; Brussa A; Comisso I; Auci E; Sartori M; Bove T
    Crit Care; 2024 Jul; 28(1):221. PubMed ID: 38970010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
    Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
    J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
    Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
    Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa.
    Blackburn M
    Am J Emerg Med; 2022 Dec; 62():144.e1-144.e3. PubMed ID: 36038405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.
    Milkovits AE; Sugrue D; Faris J; Schad JL; McAllister KB
    J Pharm Pract; 2024 Oct; 37(5):1099-1106. PubMed ID: 38241183
    [No Abstract]   [Full Text] [Related]  

  • 52. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
    Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
    Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors.
    Hormese M; Littler A; Doane B; Glowacki N; Khimani A; Vivacqua N; Rudenberg K
    J Thromb Thrombolysis; 2021 Oct; 52(3):828-835. PubMed ID: 33725284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
    Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
    Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
    Santibanez M; Lesch CA; Lin L; Berger K
    J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.
    Sarhan K; Mohamed RG; Elmahdi RR; Mohsen Y; Elsayed A; Zayed DM; Elkholi MA; Gabr N; El-Bialy EM; Serag I
    Neurocrit Care; 2024 Oct; ():. PubMed ID: 39379749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.